{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T11:57:53Z","timestamp":1765454273714,"version":"3.46.0"},"reference-count":23,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"unspecified","delay-in-days":70,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Taisho Pharmaceutical Co., Ltd."}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2025,11,19]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the efficacy of ozoralizumab in patients with rheumatoid arthritis (RA), with or without large joint involvement (LJI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A post hoc analysis was conducted for Japanese patients with RA who received ozoralizumab 30 mg every 4 weeks for 52 weeks in the previous OHZORA (with concomitant methotrexate) and NATSUZORA (without concomitant methotrexate) randomised trials. Patients were subgrouped by LJI, defined as the presence of swelling in the shoulder, elbow, knee or ankle. Disease activity, physical dysfunction, blood inflammatory marker levels and progression of joint destruction during treatment were examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The numbers of patients included were 152 for the OHZORA trial (111 with LJI, 41 without LJI) and 94 for the NATSUZORA trial (72 with LJI, 22 without LJI). The completion rates of both trials did not differ significantly between the patient groups. Baseline Clinical Disease Activity Index scores were significantly higher in patients with LJI than in those without LJI, but this difference was not present as early as day 3 of ozoralizumab treatment and at most subsequent assessments. A similar trend was observed for patient-reported\/physician-reported outcomes and Health Assessment Questionnaire. Blood interleukin-6 and matrix metalloproteinase-3 levels in patients with LJI continuously decreased during treatment. Changes in modified Total Sharp Score at week 24 were similar between the groups in the OHZORA trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ozoralizumab has the potential to improve disease activity and physical dysfunction and prevent joint destruction in patients, regardless of the presence of LJI, and is a reasonable treatment option, even for patients with LJI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>jRCT2080223971 and jRCT2080223973.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-006218","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T11:45:19Z","timestamp":1765453519000},"page":"e006218","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of ozoralizumab in rheumatoid arthritis patients with large joint involvement: a post hoc analysis of OHZORA and NATSUZORA trials"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2426-1024","authenticated-orcid":false,"given":"Kosuke","family":"Ebina","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, Osaka University Faculty of Medicine Graduate School of Medicine, Suita, Japan"},{"name":"Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, Suita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Taisho Pharmaceutical Co., Ltd, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanao","family":"Kyuuma","sequence":"additional","affiliation":[{"name":"Taisho Pharmaceutical Co., Ltd, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuko","family":"Horiuchi","sequence":"additional","affiliation":[{"name":"Taisho Pharmaceutical Co., Ltd, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rumiko","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Taisho Pharmaceutical Co., Ltd, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5741-5969","authenticated-orcid":false,"given":"Yuki","family":"Etani","sequence":"additional","affiliation":[{"name":"Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, Suita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9938-6780","authenticated-orcid":false,"given":"Takaaki","family":"Noguchi","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Osaka University Faculty of Medicine Graduate School of Medicine, Suita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Molecular Targeted Therapeutics, University of Occupational and Environmental Health Japan, Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Keio University School of Medicine, Tokyo, Japan"},{"name":"Saitama Medical University, Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"2025121103451072000_11.4.e006218.1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)30173-8. PubMed PMID: 27156434."},{"key":"2025121103451072000_11.4.e006218.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.13103"},{"key":"2025121103451072000_11.4.e006218.3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/36.8.855"},{"key":"2025121103451072000_11.4.e006218.4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.9.998"},{"key":"2025121103451072000_11.4.e006218.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.066704"},{"key":"2025121103451072000_11.4.e006218.6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes228"},{"key":"2025121103451072000_11.4.e006218.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.21589"},{"key":"2025121103451072000_11.4.e006218.8","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-04862-y"},{"key":"2025121103451072000_11.4.e006218.9","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.15097","article-title":"Association of large joint involvement at the start of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors with disease activity and drug retention in patients with rheumatoid arthritis: The ANSWER cohort study","volume":"27","author":"Shirasugi","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"2025121103451072000_11.4.e006218.10","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/art.42273","article-title":"Phase II\/III Results of a Trial of Anti-Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis","volume":"74","author":"Takeuchi","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025121103451072000_11.4.e006218.11","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roac119"},{"key":"2025121103451072000_11.4.e006218.12","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roac126"},{"key":"2025121103451072000_11.4.e006218.13","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-023-03036-4","article-title":"Efficacy and pharmacokinetics of ozoralizumab, an anti-TNF\u03b1 NANOBODY\u00ae compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials","volume":"25","author":"Takeuchi","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"2025121103451072000_11.4.e006218.14","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jcph.2380","article-title":"Population Pharmacokinetics of Ozoralizumab in Patients with Rheumatoid Arthritis","volume":"64","author":"Takeuchi","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"2025121103451072000_11.4.e006218.15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.853008","article-title":"Ozoralizumab, a Humanized Anti-TNF\u03b1 NANOBODY\u00ae Compound, Exhibits Efficacy Not Only at the Onset of Arthritis in a Human TNF Transgenic Mouse but Also During Secondary Failure of Administration of an Anti-TNF\u03b1 IgG","volume":"13","author":"Ishiwatari-Ogata","year":"2022","journal-title":"Front Immunol"},{"key":"2025121103451072000_11.4.e006218.16","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-23152-6","article-title":"A novel anti-TNF-\u03b1 drug ozoralizumab rapidly distributes to inflamed joint tissues in a mouse model of collagen induced arthritis","volume":"12","author":"Oyama","year":"2022","journal-title":"Sci Rep"},{"key":"2025121103451072000_11.4.e006218.17","doi-asserted-by":"crossref","first-page":"150454","DOI":"10.1016\/j.bbrc.2024.150454","article-title":"Structural design of the anti-TNF\u03b1 therapeutic NANOBODY\u00ae compound, ozoralizumab, to support its potent and sustained clinical efficacy","volume":"734","author":"Mima","year":"2024","journal-title":"Biochem Biophys Res Commun"},{"key":"2025121103451072000_11.4.e006218.18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.9.4793"},{"key":"2025121103451072000_11.4.e006218.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780241215"},{"key":"2025121103451072000_11.4.e006218.20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40259-024-00648-3","article-title":"Next-Generation Anti-TNF\u03b1 Agents: The Example of Ozoralizumab","volume":"38","author":"Tsumoto","year":"2024","journal-title":"BioDrugs"},{"key":"2025121103451072000_11.4.e006218.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211485"},{"key":"2025121103451072000_11.4.e006218.22","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18050905","article-title":"Matrix Metalloproteinase Gene Activation Resulting from Disordred Epigenetic Mechanisms in Rheumatoid Arthritis","volume":"18","author":"Araki","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2025121103451072000_11.4.e006218.23","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000363","article-title":"Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study","volume":"3","author":"Takahashi","year":"2017","journal-title":"RMD Open"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-006218","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T11:45:20Z","timestamp":1765453520000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-006218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,11]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/rmdopen-2025-006218"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-006218","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}